Lilotomab

Lutetium-177_satetraxetan.svg

Lilotomab is a monoclonal antibody used in the treatment of certain types of non-Hodgkin lymphoma. It is specifically designed to target the CD37 antigen, which is commonly found on the surface of B-cell lymphomas.

Mechanism of Action

Lilotomab works by binding to the CD37 antigen on the surface of B-cells. This binding triggers an immune response that leads to the destruction of the cancerous B-cells. The antibody can also be used in combination with other treatments, such as radioimmunotherapy, to enhance its effectiveness.

Clinical Use

Lilotomab is primarily used in the treatment of non-Hodgkin lymphoma, particularly in cases where the disease has not responded to other forms of treatment. It is often used in combination with other therapeutic agents to improve patient outcomes.

Development and Approval

Lilotomab is currently under investigation in clinical trials. It has shown promise in early-phase studies, but further research is needed to confirm its efficacy and safety. The development of Lilotomab is part of ongoing efforts to improve treatment options for patients with non-Hodgkin lymphoma.

Side Effects

As with other monoclonal antibodies, Lilotomab can cause a range of side effects. Common side effects include infusion reactions, fatigue, and nausea. More serious side effects may include infections and hematologic toxicities. Patients receiving Lilotomab are closely monitored for any adverse reactions.

Research and Future Directions

Ongoing research is focused on optimizing the use of Lilotomab in combination with other therapies. Studies are also exploring its potential use in other types of B-cell malignancies. The goal is to enhance the effectiveness of Lilotomab while minimizing side effects.

See Also

• Monoclonal antibody
• Non-Hodgkin lymphoma
• B-cell
• Radioimmunotherapy